308 related articles for article (PubMed ID: 31957179)
1. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
[TBL] [Abstract][Full Text] [Related]
2. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.
Fu QF; Liu Y; Fan Y; Hua SN; Qu HY; Dong SW; Li RL; Zhao MY; Zhen Y; Yu XL; Chen YY; Luo RC; Li R; Li LB; Deng XJ; Fang WY; Liu Z; Song X
J Hematol Oncol; 2015 Mar; 8():22. PubMed ID: 25887760
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
4. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
Li X; Zhu W; Chen Z; Luo L; Huang J; Zhang F; Li M; Guo Y; Guo L
Anticancer Drugs; 2014 Nov; 25(10):1152-64. PubMed ID: 25054270
[TBL] [Abstract][Full Text] [Related]
6. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
7. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
[TBL] [Abstract][Full Text] [Related]
8. HuR affects chemoresistance of small cell lung cancer by regulating FGFRL1 expression.
Duan XH; Chen R; Li DS; Luo AH; Guo LL
Exp Ther Med; 2022 Oct; 24(4):638. PubMed ID: 36160905
[TBL] [Abstract][Full Text] [Related]
9. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol inhibits viability and induces apoptosis in the small‑cell lung cancer H446 cell line via the PI3K/Akt/c‑Myc pathway.
Li W; Li C; Ma L; Jin F
Oncol Rep; 2020 Nov; 44(5):1821-1830. PubMed ID: 32901891
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of α-enolase affects the biological activity of breast cancer cells by attenuating PI3K/Akt signaling pathway.
Zang HY; Gong LG; Li SY; Hao JG
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):249-257. PubMed ID: 31957838
[TBL] [Abstract][Full Text] [Related]
12. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
13. CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer.
Deng T; Shen P; Li A; Zhang Z; Yang H; Deng X; Peng X; Hu Z; Tang Z; Liu J; Hou R; Liu Z; Fang W
Theranostics; 2021; 11(16):8112-8128. PubMed ID: 34335983
[TBL] [Abstract][Full Text] [Related]
14. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.
Xiao F; Bai Y; Chen Z; Li Y; Luo L; Huang J; Yang J; Liao H; Guo L
Eur J Cancer; 2014 May; 50(8):1541-54. PubMed ID: 24559685
[TBL] [Abstract][Full Text] [Related]
16. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
[TBL] [Abstract][Full Text] [Related]
17. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
[TBL] [Abstract][Full Text] [Related]
20. Enolase-1 is a therapeutic target in endometrial carcinoma.
Zhao M; Fang W; Wang Y; Guo S; Shu L; Wang L; Chen Y; Fu Q; Liu Y; Hua S; Fan Y; Liu Y; Deng X; Luo R; Mei Z; Jiang Q; Liu Z
Oncotarget; 2015 Jun; 6(17):15610-27. PubMed ID: 25951350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
